Abstract:You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology III1 Apr 2018MP65-04 LONG NON-CODING RNA GAS5 MODULATES GEMCITABINE EFFICACY IN BLADDER CANCER VIA REGULATION OF DEOXYCYTIDINE KINASE EXPRESSION Wei Chen, Junlong Zhuang, Wenmin Cao, Wenli Diao, and Hongqian Guo Wei ChenWei Chen More articles by this author , Junlong ZhuangJunlong Zhuang More articles by this author , Wenmin CaoWenmin Cao More articles by this author , Wenli DiaoWenli Diao More articles by this author , and Hongqian GuoHongqian Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2070AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Gemcitabine is a common used agent for therapy in bladder cancer. Our objective was to characterize the ability of Long non-coding RNA GAS5 to modulate the gemcitabine efficacy. METHODS Expression of GAS5 was analyzed using real-time quantitative polymerase chain reaction (RT-qPCR) in 30 patients following radical cystectomy and gemcitabine treatment. All subjects signed written informed consent. The study was approved by the Hospital Ethics Boards prior to initiation. The correlation between GAS5 and deoxycytidine kinase (DCK) was further examined by evaluating DCK expression in cells that either overexpressed or knocked down GAS5. Gemcitabine efficacy was identified by CCK-8 assays. DCK and HuR were analyzed by western blotting and immunofluorescence. RESULTS GAS5 was significantly downregulated in bladder cancer tissues compared with the paired adjacent non-tumorous tissues. Lower GAS5 expression levels were associated with advanced pathological stages and poor overall survival (Fig. 1). LncRNA GAS5 expression is also lower in T24, 5637 and SW780 compared with the human normal urothelial cell line (Sv-Huc-1). GAS5 level was well correlated with the sensitivity of the cancer cells toward gemcitabine. Gemcitabine can dose-dependently increase GAS5 level in bladder cancer cells. Of note, pretreated gemcitabine attenuated GAS5-induced with a second dose of gemcitabine. GAS5-overexpressing cells displayed an elevated level of cell death induced by gemcitabine. Accordingly, knockdown of GAS5 in bladder cancer cells by small interfering RNA conferred tolerance to gemcitabine-induced cytotoxicity (Figure 3C, 3D). DCK is the rate-limiting enzyme responsible for conversion of gemcitabine to active antimetabolite. By knocking down GAS5 in bladder cancer cells, we experimentally confirmed that GAS5 regulates DCK expression. Furthermore, we revealed that proapoptotic function of GAS5 was correlated with promoting HuR nuclear export and the biological consequence of deoxycytidine kinase expression (Fig. 2). CONCLUSIONS This study shows that long non-coding RNA GAS5 modulates HuR-mediated DCK expression, and GAS5 low expression confers gemcitabine tolerance. The expression of GAS5 may represent a novel companion diagnostic and target to undermine chemotherapy resistance. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e859-e860 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Wei Chen More articles by this author Junlong Zhuang More articles by this author Wenmin Cao More articles by this author Wenli Diao More articles by this author Hongqian Guo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Additional File 5: of Long Noncoding RNA GSTM3TV2 Upregulates LAT2 and OLR1 by Competitively Sponging Let-7 to Promote Gemcitabine Resistance in Pancreatic Cancer

Long Noncoding RNA SATB1-AS1 Contributes to the Chemotherapy Resistance Through the Microrna-580/ 2'-5'-oligoadenylate Synthetase 2 Axis in Acute Myeloid Leukemia.

Long Non-Coding RNA BC087858 Induces Non-T790m Mutation Acquired Resistance to EGFR-TKIs by Activating PI3K/AKT and MEK/ERK Pathways and EMT in Non-Small-cell Lung Cancer

Additional File 14 of M6a Eraser FTO Impairs Gemcitabine Resistance in Pancreatic Cancer Through Influencing NEDD4 Mrna Stability by Regulating the PTEN/PI3K/AKT Pathway

Additional File 7 of METTL3/IGF2BP3 Axis Inhibits Tumor Immune Surveillance by Upregulating N6-methyladenosine Modification of PD-L1 Mrna in Breast Cancer

Regulation of microRNA-598-3p on biological characteristics of the gastric cancer cells through targeting RNA polymerases Ⅱ the fifth subunit mediating protein gene

Long Non-Coding SBF2-AS1 Acting As a Competing Endogenous RNA to Sponge Microrna-142-3p to Participate in Gemcitabine Resistance in Pancreatic Cancer Via Upregulating TWF1

Supplementary Table S1 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

High Expression of SLC34A2 Contributes to Chemoresistance of Non-Small Cell Lung Cancer Against Gefitinib: the Critical Role of Mir-124-3p

Supplementary Table S2 from METTL1-Mediated M<sup>7</sup>g Trna Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Additional File 1 of Long Non-Coding RNA NORAD/miR-224-3p/MTDH Axis Contributes to CDDP Resistance of Esophageal Squamous Cell Carcinoma by Promoting Nuclear Accumulation of Β-Catenin

m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

The M(6)a Methyltransferase METTL3 Promotes Gastric Cancer Progression Through Facilitating Primary Microrna Maturation

Additional File 5 of Dysregulation and Prometastatic Function of Glycosyltransferase C1GALT1 Modulated by Chp1bp3/ Mir-1-3p Axis in Bladder Cancer

MP65-04 LONG NON-CODING RNA GAS5 MODULATES GEMCITABINE EFFICACY IN BLADDER CANCER VIA REGULATION OF DEOXYCYTIDINE KINASE EXPRESSION

MiR-17- 5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells

LINC02535/miR-30a-5p/GALNT3 Axis Contributes to Lung Adenocarcinoma Progression Via the NF- Κ B Signaling Pathway.

LncRNA MEG3 contributes to drug resistance in acute myeloid leukemia by positively regulating ALG9 through sponging miR‐155

Long Non-coding RNA DLEU2L Targets Mir-210-3p to Suppress Gemcitabine Resistance in Pancreatic Cancer Cells Via BRCA2 Regulation

Down-Regulation Of Microrna-20a In Gemcitabine-Resistant Pancreatic Cancer In In Vitro Microrna Integrative Analysis

Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma